Genetic variation at KIT locus may predispose to melanoma

Pigment Cell and Melanoma Research

Volumn 26, Issue 1, 2013, Pages 88-96

  Bourillon, Agnes ^a   Hu, Hui Han ^a,b,c   Hetet, Gilles ^a   Lacapere, Jean Jacques ^c   André, Jocelyne ^b,c   Descamps, Vincent ^a,b   Basset Seguin, Nicole ^b,c,d   Ogbah, Zighereda ^e   Puig, Susana ^e,f   Saiag, Philippe ^g   Bagot, Martine ^b,c,d   Bensussan, Armand ^b,c   Grandchamp, Bernard ^a,b   Dumaz, Nicolas ^b,c,d   Soufir, Nadem ^a,b,c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^g HÔPITAL AMBROISE PARÉ   (France)

Author keywords

KIT; Melanoma; Nevus; Predisposition

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL LINEAGE; CONTROLLED STUDY; EXOME; FEMALE; GENE LOCUS; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; EXOME; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; PHOSPHORYLATION; PIGMENTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS;

EID: 84871414831     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12032     Document Type: Article

References (43)

1. Abdel-Rahman, M.H., Pilarski, R., Cebulla, C.M., Massengill, J.B., Christopher, B.N., Boru, G., Hovland, P., and Davidorf, F.H. (2011). Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856-859.
2. Alexeev, V., and Yoon, K. (2006). Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J. Invest. Dermatol. 126, 1102-1110.
3. Aoki, H., Hara, A., Motohashi, T., and Kunisada, T. (2011). Protective effect of Kit signaling for melanocyte stem cells against radiation-induced genotoxic stress. J. Invest. Dermatol. 131, 1906-1915.
4. Bar-Eli, M. (1997). Molecular mechanisms of melanoma metastasis. J. Cell. Physiol. 173, 275-278.
5. Barrett, J.H., Iles, M.M., Harland, M. et al. (2011). Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 43, 1108-1113.
6. Bertolotto, C., Lesueur, F., Giuliano, S. et al. (2011). A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480, 94-98.
7. Duffy, D.L., Iles, M.M., Glass, D. et al. (2010). IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6-16.
8. Fernandez, L.P., Milne, R.L., Pita, G., Avilés, J.A., Lázaro, P., Benítez, J., and Ribas, G. (2008). SLC45A2: a novel malignant melanoma-associated gene. Hum. Mutat. 29, 1161-1167.
9. Fleischman, R.A., Gallardo, T., and Mi, X. (1996). Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. J. Invest. Dermatol. 107, 703-706.
10. Gerstenblith, M.R., Shi, J., and Landi, M.T. (2010). Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res. 23, 587-606.
11. Godshalk, S.E., Paranjape, T., Nallur, S. et al. (2011). A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 30, 1542-1550.
12. Grichnik, J.M. (2006). Kit and melanocyte migration. J. Invest. Dermatol. 126, 945-947.
13. Gudbjartsson, D.F., Sulem, P., Stacey, S.N. et al. (2008). ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886-891.
14. Guedj, M., Bourillon, A., Combadieres, C. et al. (2008). Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum. Mutat. 29, 1154-1160.
15. Guerriere-Kovach, P.M., Hunt, E.L., Patterson, J.W., Glembocki, D.J., English, J.C., 3rd, and Wick, M.R. (2004). Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am. J. Clin. Pathol. 122, 70-77.
16. Hansson, J. (2010). Familial cutaneous melanoma. Adv. Exp. Med. Biol. 685, 134-145.
17. Hemesath, T.J., Price, E.R., Takemoto, C., Badalian, T., and Fisher, D.E. (1998). MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391, 298-301.
18. Herraiz, C., Journe, F., Abdel-Malek, Z., Ghanem, G., Jimenez-Cervantes, C., and Garcia-Borron, J.C. (2011). Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol. Endocrinol. 25, 138-156.
19. Hu, H.H., Guedj, M., Descamps, V. et al. (2011). Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. J. Dermatol. Sci. 64, 127-133.
20. Jannot, A.S., Meziani, R., Bertrand, G. et al. (2005). Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur. J. Hum. Genet. 13, 913-920.
21. Larue, L., Dougherty, N., Porter, S., and Mintz, B. (1992). Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation. Proc. Natl Acad. Sci. USA 89, 7816-7820.
22. Law, M.H., Montgomery, G.W., Brown, K.M., Martin, N.G., Mann, G.J., Hayward, N.K., and Macgregor, S. (2012). Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. J. Invest. Dermatol. 132, 485-487.
23. Liu, H., Chen, X., Focia, P.J., and He, X. (2007). Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J. 26, 891-901.
24. Macgregor, S., Montgomery, G.W., Liu, J.Z. et al. (2011). Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114-1118.
25. McGill, G.G., Horstmann, M., Widlund, H.R. et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718.
26. Mol, C.D., Lim, K.B., Sridhar, V., Zou, H., Chien, E.Y., Sang, B.C., Nowakowski, J., Kassel, D.B., Cronin, C.N., and Mcree, D.E. (2003). Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31461-31464.
27. Monsel, G., Ortonne, N., Bagot, M., Bensussan, A., and Dumaz, N. (2011). c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29, 227-236.
28. Montone, K.T., Van Belle, P., Elenitsas, R., and Elder, D.E. (1997). Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod. Pathol. 10, 939-944.
29. Natali, P.G., Nicotra, M.R., Winkler, A.B., Cavaliere, R., Bigotti, A., and Ullrich, A. (1992). Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int. J. Cancer 52, 197-201.
30. Pierotti, M.A., Tamborini, E., Negri, T., Pricl, S., and Pilotti, S. (2011). Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat. Rev. Clin. Oncol. 8, 161-170.
31. Rafnar, T., Sulem, P., Stacey, S.N. et al. (2009). Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227.
32. Raimondi, S., Sera, F., Gandini, S., Iodice, S., Caini, S., Maisonneuve, P., and Fargnoli, M.C. (2008). MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int. J. Cancer 122, 2753-2760.
33. Rice, T.K., Schork, N.J., and Rao, D.C. (2008). Methods for handling multiple testing. Adv Genet 60, 293-308.
34. Roskoski, R., Jr. (2005). Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun. 338, 1307-1315.
35. Soufir, N., Meziani, R., Lacapere, J.J. et al. (2005). Association between endothelin receptor B nonsynonymous variants and melanoma risk. J. Natl Cancer Inst. 97, 1297-1301.
36. Stacey, S.N., Sulem, P., Masson, G. et al. (2009). New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41, 909-914.
37. Testa, J.R., Cheung, M., Pei, J. et al. (2011). Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022-1025.
38. Tomita, Y., and Suzuki, T. (2004). Genetics of pigmentary disorders. Am. J. Med. Genet. C Semin. Med. Genet. 131C, 75-81.
39. Udayakumar, D., Mahato, B., Gabree, M., and Tsao, H. (2011). Genetic determinants of cutaneous melanoma predisposition. Semin. Cutan. Med. Surg. 29, 190-195.
40. Wiesner, T., Obenauf, A.C., Murali, R. et al. (2011). Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021.
41. Woodman, S.E., and Davies, M.A. (2011). Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem. Pharmacol. 80, 568-574.
42. Yokoyama, S., Woods, S.L., Boyle, G.M. et al. (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480, 99-103.
43. Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., and Schlessinger, J. (2007). Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130, 323-334.